Tessel Vossenberg

Tessel Vossenberg

Auto-generated profile, based on publicly available information

Tessel Vossenberg

Department of Cardiology, Frisius Medical Center, Leeuwarden, The Netherlands (P.W., T.N.E.V.).

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2021 in Journal of Invasive Cardiology
Verified
Journal Article
Closed access
FBFloris S. Van den Brink
Floris S. Van den Brink
CZCarlo Zivelonghi
Carlo Zivelonghi
TVTessel Vossenberg
Tessel Vossenberg
GBGabe Bleeker
Gabe Bleeker
VWVivian Winia
Vivian Winia
JBJurrien Ten Berg
Jurrien Ten Berg
This study assesses whether combining venoarterial extracorporeal membrane oxygenation (VA-ECMO) with intra-aortic balloon pump (IABP) improves outcomes in ST-segment elevation myocardial infarction (STEMI) over VA-ECMO alone. from Journal of Invasive Cardiology. IABP Intra-aortic balloon pump Primary PCI VA-ECMO

1 May 2025 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
FOFederico Oliveri
Federico Oliveri
MOMartijn J.H. Van Oort
Martijn J.H. Van Oort
IAIbtihal Al Amri
Ibtihal Al Amri
BBBrian O. Bingen
Brian O. Bingen
BCBimmer E. Claessen
Bimmer E. Claessen
JMJosè M. Montero-Cabezas
Josè M. Montero-Cabezas
Intravascular lithotripsy (IVL) has been demonstrated to be effective in treating balloon-crossable calcified coronary lesions by inducing calcium fractures and facilitating stent expansion (SE), theoretically by improving coronary artery compliance (CACom). Direct evidence of this theory has not yet been provided. From the BENELUX-IVL prospective registry (NCT06577038) enrolling patients with calcified coronary artery lesions treated with IVL, intravascular ultrasound–guided cases were selected. CACom was calculated as the systo-diastolic change in the luminal area (ΔA), measured using intravascular ultrasound, relative to the corresponding change in aortic pressure (ΔP). Measurements were taken directly before (pre-CACom) and after (post-CACom) IVL therapy at the most calcified segment, where IVL pulses were administered. The primary end point was CACom modification (ΔCACom), defined as post-CACom – pre-CACom, with a correlation analysis between ΔCACom and new fractures as a key exploratory aim. Secondary analysis included assessing whether ΔCACom could predict SE at the minimum stent area (MSA) and the eccentricity index. Coronary artery compliance significantly improved after IVL therapy (median ΔCACom 0.33 [0.19-0.70] mm2/mm Hg; P < .01). Lesions showing new calcium fractures presented significantly greater ΔCACom compared to those without. ΔCACom and new calcium fractures were significantly correlated (R = 0.466; P < .01). In univariate analysis, ΔCACom was found to be a significant predictor for SE at MSA (P < .01), MSA (P = .015), and SE >80% (P = .025), but not eccentricity index (P = .157). At multivariate analysis, ΔCACom was an independent predictor of SE (R = 0.420; P = .044) and SE >80% at MSA (OR, 6.58 [1.24-34.90]; P = .043). In heavily calcified coronary lesions treated with IVL, ΔCACom is an independent predictor of SE.

21 January 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
CCC. Crooijmans
C. Crooijmans
TJTijn P. J. Jansen
Tijn P. J. Jansen
JMJoan G. Meeder
Joan G. Meeder
Paradies ValeriaParadies Valeria
Paradies Valeria
AVAnnemiek de Vos
Annemiek de Vos
FNFor Nl‐Cft
For Nl‐Cft
Background: A coronary function test (CFT) is the recommended diagnostic test to identify coronary vasomotor dysfunction as a cause of symptoms in patients with angina and nonobstructive coronary arteries (ANOCA). Acetylcholine is the commonly used pharmacological agent for spasm provocation. We aimed to investigate an association between severity of symptoms and provocative acetylcholine dose. Methods and Results: We included ANOCA patients undergoing clinically indicated CFT from the Netherlands Registry of Invasive Coronary Vasomotor Function Testing: NL‐CFT. Patients with epicardial spasm (n=251) were divided according to acetylcholine spasm triggering dose: low (2–20 mcg, EpiLOW), middle (100 mcg, EpiMIDDLE) or high (200 mcg, EpiHIGH). Patients with microvascular spasm (n=157) were analyzed irrespective of triggering dose. The patient groups were compared to each other and to a control group with negative CFT results (n=101). We assessed mean Seattle Angina Questionnaire angina frequency and summary scores at baseline and follow‐up and the proportion of patients improving or deteriorating. An inverse relationship between provocation dosage and angina frequency at baseline was found in epicardial spasm: the lower the triggering dose, the more frequently patients experienced angina (EpiLOW 48±20, EpiMIDDLE 53±21, EpiHIGH 57±19, microvascular spasm 61±21, controls 64±21, overall P =0.003). A trend was seen toward most patients improving in the high triggering dose group, and most patients deteriorating in the low triggering dose group. Conclusions: A significant dose‐dependent relationship between spasm provocation and anginal complaints exists. Acetylcholine provocation dose could be incorporated as a risk stratification factor or surrogate outcome in future clinical trials. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06083155.

1 June 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
FAFleur W. Adriaansen
Fleur W. Adriaansen
CCCaïa Crooijmans
Caïa Crooijmans
TJTijn P.J. Jansen
Tijn P.J. Jansen
BYBehruz Yosofi
Behruz Yosofi
JMJoan G. Meeder
Joan G. Meeder
FNFor Nl-Cft
For Nl-Cft
BACKGROUND: Coronary vasomotor dysfunction is diagnosed by a coronary function testing (CFT). However, protocols vary, and the influence of access site and concomitant vasodilator medication on the diagnostic yield and safety of CFT is unclear. This study assessed the diagnostic yield and safety of CFT by radial access with intraarterial calcium channel blockers compared with CFT by femoral access. METHODS: Data were obtained from the Netherlands Registry of Invasive Coronary Vasomotor Function Testing, a Dutch multicenter collaboration on CFT. Patients who underwent CFT between December 2020 and July 2025 were included. RESULTS: A total of 1885 patients were included, 1436 (76.2%) with primary radial access and 380 (20.2%) with primary femoral access. In 69 (3.7%) patients conversion from radial to femoral access was necessary. The conversion group was analyzed separately. The total diagnostic yield of coronary vasomotor dysfunction was 78.5%. There was no significant difference in the prevalence of coronary vasomotor dysfunction between patients with primary radial versus femoral access (79.2% versus 75.3%; P =0.1). There was also no difference in total diagnostic yield between the group without conversion and the conversion group (78.4% versus 82.6%; P =0.4); however, spasm was more prevalent in the conversion group (67.7% versus 79.4%; P =0.04). There were no differences in CFT complication rates between groups. CONCLUSIONS: Primary radial access with routine administration of calcium channel blockers was not associated with a lower diagnostic yield in CFT than primary femoral access. Procedural safety was comparable.

23 July 2025 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
MOMartijn J.H. van Oort
Martijn J.H. van Oort
APAkshay A.S. Phagu
Akshay A.S. Phagu
FOFederico Oliveri
Federico Oliveri
BBBrian O. Bingen
Brian O. Bingen
VPValeria Paradies
Valeria Paradies
JMJose Montero-Cabezas
Jose Montero-Cabezas
This study aimed to evaluate the incidence of complications associated with intravascular lithotripsy (IVL) therapy, assess clinical outcomes, and identify predictors of complications in a real-world patient cohort. Patients undergoing IVL between May 2019 and September 2024 were enrolled from the BENELUX-IVL registry and categorized based on the occurrence of complications following IVL and concomitant therapy. End points were achievement of residual diameter stenosis <30% on quantitative coronary analysis and major adverse cardiovascular events (MACE) at 1-year follow-up. Kaplan-Meier and binary logistic regression analyses were performed to compare outcomes and to identify predictors of complications. The study included 509 patients (73 ± 9 years, 75% male). Complications occurred in 33 patients (6%), of which 6 complications occurred immediately after IVL (1%). The most frequent complications were flow-limiting coronary dissections (n = 9, 2%), hemodynamic instability (n = 9, 2%), and coronary perforations (n = 7, 1%). These were effectively managed with 30 interventions, resulting in favorable procedural outcomes. Among patients with complications and available quantitative coronary analysis data, residual diameter stenosis <30% was achieved in 28 of 29 lesions (97%). One-year cumulative MACE was 11% (39 patients) and was significantly higher in patients with complications (P < .001), mainly driven by in-hospital events (P < .001). Larger predilatation balloon diameters (P = .032) were associated with complications. In this real-world registry, complications following IVL and concomitant therapy were infrequent. Patients with procedural complications had significantly higher 1-year MACE, primarily driven by in-hospital events. Larger predilatation balloon diameters were a significant predictor of complications.

9 November 2026 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
APAkshay A. S. Phagu
Akshay A. S. Phagu
JFJessica P. Forouzanfar
Jessica P. Forouzanfar
MOMartijn J. H. van Oort
Martijn J. H. van Oort
FOFederico Oliveri
Federico Oliveri
BBBrian O. Bingen
Brian O. Bingen
JMJose Montero-Cabezas
Jose Montero-Cabezas
Background: The United Kingdom–British Cardiovascular Intervention Society complex high‐risk indicated percutaneous coronary intervention (UK‐BCIS CHIP) score was developed to identify patient‐ and procedural factors to predict short‐term adverse outcomes in patients undergoing high risk percutaneous coronary intervention (PCI). The performance of the UK‐BCIS CHIP score in a patient population treated with intravascular lithotripsy (IVL) for severe coronary calcification remains unknown. Aims: To evaluate the prognostic performance of the UK‐BCIS CHIP score in patients undergoing IVL‐assisted PCI for severe coronary calcification, and to assess procedural and 1‐year clinical outcomes across CHIP score categories. Methods: This international, multicenter, prospective study included consecutive patients undergoing IVL‐assisted PCI between May 2019 and December 2025 from the BENELUX‐IVL registry. Patients were stratified according to UK‐BCIS CHIP score categories (0, 1–2, 3–4, and ≥ 5). The primary endpoint was 1‐year major adverse cardiac events (MACE), defined as a composite of cardiovascular death, non‐fatal myocardial infarction, or clinically driven target vessel revascularization. Secondary endpoints included all‐cause mortality, procedural outcomes, and periprocedural complications. Discrimination of the UK‐BCIS CHIP score was assessed using the AUC for in‐hospital events and the Harrell's C‐index for 1‐year outcomes. Results: A total of 911 patients were included. Higher UK‐BCIS CHIP scores were associated with increased clinical comorbidity, lesion complexity, and procedural intensity. Procedural, device, and technical success rates were comparable across UK‐BCIS CHIP score categories (85.1%, 94.4%, and 85.7% overall; p = 0.850, p = 0.813, and p = 0.781, respectively). Complications requiring intervention occurred in 5.5% of patients and did not differ significantly across CHIP score categories ( p = 0.347). The 1‐year cumulative incidence of MACE, accounting for all‐cause death as a competing risk, did not differ significantly across UK‐BCIS CHIP score categories (Gray's test p = 0.53). Conclusion: In IVL‐assisted PCI, the UK‐BCIS CHIP score effectively identifies patients with increased clinical and procedural complexity but shows limited discrimination for mid‐term ischemic outcomes. IVL‐assisted PCI is safe and effective across the full spectrum of CHIP risk, while long‐term prognosis appears primarily driven by underlying comorbidity burden.